Luke Seikkula
Chief Operating Officer at LA JOLLA PHARMACEUTICAL COMPANY
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael Hearne | M | 61 | 4 years | |
| Kathryn Collins | F | - | 25 years | |
| Scott Leinenweber | M | - | 27 years | |
| Philip Boudreau | M | 51 | 27 years | |
| Michael E. Schick | M | 57 |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 15 years |
| Marianne Zhen | F | 55 | 2 years | |
| Andrea Wainer | F | - | 27 years | |
| Michael A. Grabow | M | - | 11 years | |
| Pavel Raifeld | M | 40 | 2 years | |
| Paula Rusu | F | - | 4 years | |
| Tony Hodges | M | - | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Thomas Riga | M | 48 | 10 years | |
| Joseph W. Turgeon | M | 66 | 9 years | |
| Jeffrey Leiden | M | 68 | 6 years | |
| Jennifer Carver | F | 70 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 18 years |
| George Tidmarsh | M | 64 | 7 years | |
| Kurt Gustafson | M | 56 | 9 years | |
| Larry G. Edwards | M | 52 | 3 years | |
| Dennis Mulroy | M | 69 | 5 years | |
| Elaine R. Leavenworth | F | 65 | 27 years | |
| Fred B. Parks | M | 76 | 1 years | |
| Raymond Cohen | M | 65 | 7 years | |
| Gilles Gagnon | M | 70 | - | |
| Cecilia Gonzalo | F | 49 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 years |
| John B. Thomas | M | - | 18 years | |
| Roxanne Austin | F | 63 | 22 years | |
| Nishan de Silva | M | 51 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 years |
| Robert H. Rosen | M | 68 | 8 years | |
| David Stout | M | 69 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 3 years |
| Krishan K. Arora | M | 83 | 3 years | |
| Steven Fruchtman | M | 73 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 4 years |
| Robert Fralin | M | - | - | |
| Brian Yoor | M | 54 | 23 years | |
| Dolatrai Vyas | M | 80 | 9 years | |
| Laura Douglass | F | 59 | 9 years | |
| Sandra Vedrick | F | - | 6 years | |
| Steven M. Rauscher | M | 70 | 18 years | |
| Craig Johnson | M | 62 | 9 years | |
| David Ramsay | M | 59 | 3 years | |
| Leonard M. Greenstein | M | 48 | 7 years | |
| David A. L. Owen | M | 85 | - | |
| Ricardo J. Gonzalez | M | 53 | 6 years | |
| Anton G. Gueth | M | 67 | 1 years | |
| Roy S. Roberts | M | 84 | - | |
| Robert Parkinson | M | 73 | 25 years | |
| Tom R. Hodgson | M | 82 | 27 years | |
| Timothy Patrick Lynch | M | 54 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 years |
| Paul Clark | M | 76 | 14 years | |
| Duane L. Burnham | M | 82 | 9 years | |
| Irene C. Kerr | F | 74 | 10 years | |
| Azita Saleki-Gerhardt | M | 60 | 19 years | |
| Shi-Chung Ng | M | 69 | 11 years | |
| Katarzyna Mazur-Hofsaess | M | 60 | 9 years | |
| Anthony Barnes | M | 69 | 2 years | |
| David Pearce | M | - | 16 years | |
| Jean-Yves F. Pavée | M | 60 | - | |
| Bruce H. Phelps | M | - | 12 years | |
| David Thompson | M | 82 | 21 years | |
| Robert J. Koska | M | 66 | - | |
| Jay B. Johnston | M | 77 | 24 years | |
| Joseph M. Fortunak | M | 69 | 4 years | |
| Nancy Avila | F | 57 | 22 years | |
| Stan Bukofzer | M | 67 | 9 years | |
| Karen Peterson | F | - | 30 years | |
| Jennifer Mound Smoter | F | - | 14 years | |
| Joseph M. Nemmers | M | 69 | - | |
| Sharon Larkin | F | 60 | 23 years | |
| Dennis Kim | M | 55 | 1 years | |
| Jeffrey Stewart | M | - | - | |
| Perry Karsen | M | 69 | 11 years | |
| Bruce A. Beutel | M | 60 | 12 years | |
| Robert G. Wilkins | M | 69 | - | |
| David Laskow-Pooley | M | 69 | 6 years | |
| Peter S. DiStefano | M | 66 | 5 years | |
| O. Ralph Edwards | M | 89 | - | |
| James Tyree | M | 71 | 12 years | |
| William C. Houghton | M | 81 | 11 years | |
| Bruce G. McCarthy | M | - | 7 years | |
| James J. Egan | M | 73 | 9 years | |
| Risa Stack | M | 55 | - | |
| Todd Davis | M | 63 | 5 years | |
| Yat Sun Or | M | 72 | 14 years | |
| Jaime Contreras | F | 67 | 12 years | |
| Joy Amundson | F | 69 | 16 years | |
| John Leonard | M | 66 | 20 years | |
| David Milligan | M | 83 | 17 years | |
| Joe R. Sanders | M | - | 10 years | |
| S. Ken Tanaka | M | 72 | - | |
| Mark McCamish | M | 72 | 7 years | |
| Douglas Liu | M | 62 | 10 years | |
| Jacob John Plattner | M | 77 | 21 years | |
| Michael Williams | M | - | 11 years | |
| Eugene Sun | M | 65 | 12 years | |
| Preston T. Simons | M | - | 15 years | |
| Christopher Kuebler | M | 70 | 8 years | |
| Jeff Smith | M | 64 | 5 years | |
| R. James Danehy | M | - | 21 years | |
| Chung Chiang Hsu | M | 75 | 15 years | |
| Margaret Mary Taylor | F | 67 | 7 years | |
| Tejal Vakharia | M | 51 | 10 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Luke Seikkula
- Personal Network
